BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 26022286)

  • 1. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C; Massard C
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.
    Pinto Á
    Cancer Biol Ther; 2014 Feb; 15(2):149-55. PubMed ID: 24100689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New agents for prostate cancer.
    Agarwal N; Di Lorenzo G; Sonpavde G; Bellmunt J
    Ann Oncol; 2014 Sep; 25(9):1700-1709. PubMed ID: 24658665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
    Dellis A; Papatsoris AG
    Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
    Saad F; Fizazi K
    Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on systemic therapy for advance prostate cancer.
    Carthon B; Rossi PJ
    Curr Probl Cancer; 2015; 39(1):52-62. PubMed ID: 25637932
    [No Abstract]   [Full Text] [Related]  

  • 10. New developments in castrate-resistant prostate cancer.
    Shore N; Mason M; de Reijke TM
    BJU Int; 2012 Jun; 109 Suppl 6():22-32. PubMed ID: 22672122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequences and combinations of multifaceted therapy in advanced prostate cancer.
    Vaishampayan UN
    Curr Opin Oncol; 2015 May; 27(3):201-8. PubMed ID: 25811344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and problems of new hormonal agents for the treatment of castration resistant prostate cancer].
    Hakariya T; Sakai H
    Nihon Rinsho; 2016 Jan; 74(1):137-42. PubMed ID: 26793894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy].
    Kübler H; Miller K
    Urologe A; 2013 Nov; 52(11):1517-8, 1520-1, 1524-6 passim. PubMed ID: 24166056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA; Dzik C; Rathkopf D; Scher HI
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.
    Kim W; Ryan CJ
    Cancer; 2015 Feb; 121(3):361-71. PubMed ID: 25236176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.